10x Genomics (NASDAQ:TXG) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate of $(0.48) by 41.67 percent. This is a 44 percent increase over losses of $(0.50) per share from the same period last year. The company reported quarterly sales of $154.88 million which beat the analyst consensus estimate of $132.45 million by 16.93 percent. This is a 9.84 percent increase over sales of $141.01 million the same period last year.